FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018248363> ?p ?o ?g. }

• W2018248363 endingPage "711" @default.
• W2018248363 startingPage "703" @default.
• W2018248363 abstract "Abstract Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)–streptavidin (SA) conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a strategy to decrease relapse and toxicity. α-emitting radionuclides exhibit high cytotoxicity coupled with a short path length, potentially increasing the therapeutic index and making them an attractive alternative to β-emitting radionuclides for patients with acute myeloid leukemia. Accordingly, we have used 213Bi in mice with human leukemia xenografts. Results demonstrated excellent localization of 213Bi-DOTA-biotin to tumors with minimal uptake into normal organs. After 10 minutes, 4.5% ± 1.1% of the injected dose of 213Bi was delivered per gram of tumor. α-imaging demonstrated uniform radionuclide distribution within tumor tissue 45 minutes after 213Bi-DOTA-biotin injection. Radiation absorbed doses were similar to those observed using a β-emitting radionuclide (90Y) in the same model. We conducted therapy experiments in a xenograft model using a single-dose of 213Bi-DOTA-biotin given 24 hours after anti-CD45 Ab-SA conjugate. Among mice treated with anti-CD45 Ab-SA conjugate followed by 800 μCi of 213Bi- or 90Y-DOTA-biotin, 80% and 20%, respectively, survived leukemia-free for more than 100 days with minimal toxicity. These data suggest that anti-CD45 PRIT using an α-emitting radionuclide may be highly effective and minimally toxic for treatment of acute myeloid leukemia." @default.
• W2018248363 created "2016-06-24" @default.
• W2018248363 creator A5004025497 @default.
• W2018248363 creator A5005310150 @default.
• W2018248363 creator A5007024434 @default.
• W2018248363 creator A5009266851 @default.
• W2018248363 creator A5014614433 @default.
• W2018248363 creator A5026348141 @default.
• W2018248363 creator A5031776733 @default.
• W2018248363 creator A5036409687 @default.
• W2018248363 creator A5040412322 @default.
• W2018248363 creator A5053467199 @default.
• W2018248363 creator A5056405520 @default.
• W2018248363 creator A5062268407 @default.
• W2018248363 creator A5066548173 @default.
• W2018248363 creator A5076899086 @default.
• W2018248363 creator A5078791373 @default.
• W2018248363 creator A5084626966 @default.
• W2018248363 creator A5089665460 @default.
• W2018248363 date "2011-07-21" @default.
• W2018248363 modified "2023-10-16" @default.
• W2018248363 title "Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model" @default.
• W2018248363 cites W1573890015 @default.
• W2018248363 cites W1576593419 @default.
• W2018248363 cites W1772206618 @default.
• W2018248363 cites W1972633415 @default.
• W2018248363 cites W1978659582 @default.
• W2018248363 cites W1988173241 @default.
• W2018248363 cites W1994795175 @default.
• W2018248363 cites W1997928845 @default.
• W2018248363 cites W2004224153 @default.
• W2018248363 cites W2006928831 @default.
• W2018248363 cites W2011146291 @default.
• W2018248363 cites W2012058153 @default.
• W2018248363 cites W2021396643 @default.
• W2018248363 cites W2030765561 @default.
• W2018248363 cites W2031465902 @default.
• W2018248363 cites W2032451420 @default.
• W2018248363 cites W2033849866 @default.
• W2018248363 cites W2034558862 @default.
• W2018248363 cites W2041607504 @default.
• W2018248363 cites W2041821006 @default.
• W2018248363 cites W2050430487 @default.
• W2018248363 cites W2077102920 @default.
• W2018248363 cites W2083792010 @default.
• W2018248363 cites W2106506685 @default.
• W2018248363 cites W2107861907 @default.
• W2018248363 cites W2110646221 @default.
• W2018248363 cites W2120818780 @default.
• W2018248363 cites W2129834424 @default.
• W2018248363 cites W2133882794 @default.
• W2018248363 cites W2135368140 @default.
• W2018248363 cites W2136505615 @default.
• W2018248363 cites W2137869150 @default.
• W2018248363 cites W2140728144 @default.
• W2018248363 cites W2143509756 @default.
• W2018248363 cites W2153706622 @default.
• W2018248363 cites W2171140185 @default.
• W2018248363 cites W2273204150 @default.
• W2018248363 cites W2313092331 @default.
• W2018248363 doi "https://doi.org/10.1182/blood-2011-04-347039" @default.
• W2018248363 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3142907" @default.
• W2018248363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21613259" @default.
• W2018248363 hasPublicationYear "2011" @default.
• W2018248363 type Work @default.
• W2018248363 sameAs 2018248363 @default.
• W2018248363 citedByCount "50" @default.
• W2018248363 countsByYear W20182483632012 @default.
• W2018248363 countsByYear W20182483632013 @default.
• W2018248363 countsByYear W20182483632014 @default.
• W2018248363 countsByYear W20182483632015 @default.
• W2018248363 countsByYear W20182483632016 @default.
• W2018248363 countsByYear W20182483632017 @default.
• W2018248363 countsByYear W20182483632018 @default.
• W2018248363 countsByYear W20182483632019 @default.
• W2018248363 countsByYear W20182483632020 @default.
• W2018248363 countsByYear W20182483632021 @default.
• W2018248363 countsByYear W20182483632022 @default.
• W2018248363 countsByYear W20182483632023 @default.
• W2018248363 crossrefType "journal-article" @default.
• W2018248363 hasAuthorship W2018248363A5004025497 @default.
• W2018248363 hasAuthorship W2018248363A5005310150 @default.
• W2018248363 hasAuthorship W2018248363A5007024434 @default.
• W2018248363 hasAuthorship W2018248363A5009266851 @default.
• W2018248363 hasAuthorship W2018248363A5014614433 @default.
• W2018248363 hasAuthorship W2018248363A5026348141 @default.
• W2018248363 hasAuthorship W2018248363A5031776733 @default.
• W2018248363 hasAuthorship W2018248363A5036409687 @default.
• W2018248363 hasAuthorship W2018248363A5040412322 @default.
• W2018248363 hasAuthorship W2018248363A5053467199 @default.
• W2018248363 hasAuthorship W2018248363A5056405520 @default.
• W2018248363 hasAuthorship W2018248363A5062268407 @default.
• W2018248363 hasAuthorship W2018248363A5066548173 @default.
• W2018248363 hasAuthorship W2018248363A5076899086 @default.
• W2018248363 hasAuthorship W2018248363A5078791373 @default.
• W2018248363 hasAuthorship W2018248363A5084626966 @default.
• W2018248363 hasAuthorship W2018248363A5089665460 @default.
• W2018248363 hasBestOaLocation W20182483631 @default.

• next